A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Ormco Unveils A Refreshed Brand Identity While Staying True to Core Values

With over 60 years of distinguished history in providing the orthodontic community with a breadth of high-quality, innovative products, solutions, and education, Ormco announces a brand refresh inspired by its recommitment as an innovative partner to the orthodontic community. With a continual dedication to partnership, investment in doctor-inspired innovation, and greater clinical freedom, the company will share its new company tagline, “Driving the future of orthodontics, together” along with the unveiling of a visually refreshed brand identity at this year’s American Association of Orthodontists (AAO) in Chicago, Illinois April 21-24, 2023.

Initial elements of Ormco’s brand refresh include:

New Company Tagline: “Driving the future of orthodontics, together”

New Logo: As a prominent representation of the company and its dedication, the new logo incorporates “Together” as a recommitment to collaboration and doctor-inspired innovation.

New Brand Colors: Fresh new colors convey passion and bring to life Ormco’s commitment, dedication, innovation, and future-focused partnership for all orthodontic solutions.

“In the spirit of a brand refresh, we continue to recognize and respect the expertise of orthodontic specialists as well as their investment in advancing their education, building a vision for their practices, and growing their businesses, all while helping patients enjoy healthier beautiful smiles,” said Eric Conley, SVP Orthodontics for Envista. “The renewed commitment to our existing and new customers is to provide best-in-class products, doctor-inspired innovation, and clinical freedom by giving the flexibility to choose orthodontic solutions and preferences that best fit their practices,” he continued.

As part of its commitment to driving the future of orthodontics, Ormco continually invests in doctor-inspired innovations. Ormco has more than 1000 patents worldwide and invests millions annually in Research & Development to ensure its products continue to respond to the evolving needs of orthodontists and patients.

“By investing in innovation, Ormco is also investing in me. It’s a symbiotic partnership. We make Ormco better, and Ormco makes us better,” said Dr. Trevor Nichols of Frost Nichols Orthodontics.

“Ormco also invests in the success of orthodontists through industry-leading partnership,” said Dr. Stuart Frost of Frost Nichols Orthodontics. “As the single, trusted, and proven partner for orthodontic specialists, Ormco helps simplify vendor management so we can focus on growing our practice. We turn to Ormco as our one source for complete orthodontic needs, as well as robust educational offerings, a dedicated support team, marketing resources, a generous loyalty program, and expert-led events to keep us at the forefront of our profession,” Dr. Frost continued.

The significant investment in R&D has led to a number of industry-first and breakthrough products and features including:

  • The first true full expression system designed for faster and more precise finishing with the Damon Ultima™ System.1
  • The new Ultima™ Hook, the only repositionable hook.2
  • Proprietary ceramic bracket technology and advanced clear bracket design with Symetri™ Clear
  • TruRoot™ for Spark™ Clear Aligners that allow doctors to see actual roots in the treatment plan
  • Ormco’s new OrthoPulse® 2.0 light-powered treatment accelerator that applies low-intensity infrared technology for up to 50% faster treatment time3 and a 73% reduction in pain4

Along with the Damon Ultima System for self-ligation, Ormco’s portfolio includes the Spark TM Clear Aligner System, Titanium Orthos TM, Symetri TM Clear, AOA Lab, Mini Twin TM, and OrthoPulse® Light Accelerated OrthodonticsTM*. In addition, as part of the Envista family of companies, Ormco provides doctors with Dexis™ IS scanning solutions and Metrex™ infection prevention solutions. With a portfolio encompassing wire and bracket systems, clear aligners, light accelerated technologies, 2D and 3D imaging, infection prevention, custom appliances, and more — Ormco provides a full gamut of innovations that help doctors improve patients’ smiles by leveraging the future of orthodontics.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy